JFL Life SciencesNSE:JFLLIFE +3.47%74 Days Payable is 83.56 as of Mar. 2025, which is 1% below its 10-year median of 84.51. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 74/100 and a GF Value™ of ₹35.76 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, JFL Life Sciences ranks worse than 54.23% on this metric.
The historical rank and industry rank for JFL Life Sciences's Days Payable or its related term are showing as below:
NSE:JFLLIFE'
s Days Payable Range Over the Past 10 Years
Min: 17.75 Med: 84.51 Max: 141.53
Current: 83.56
During the past 7 years, JFL Life Sciences's highest Days Payable was 141.53. The lowest was 17.75. And the median was 84.51.
NSE:JFLLIFE's Days Payable is ranked worse than 54.23% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs NSE:JFLLIFE: 83.56
JFL Life Sciences's Days Payable
declined
from Mar. 2023 (129.33) to Mar. 2025 (83.56).
It may suggest that JFL Life Sciencesaccelerated paying its suppliers.
JFL Life Sciences Days Payable Related Terms
JFL Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
JFL Life Sciences's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a Days Payable of 83.56 as of Mar. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on JFL Life Sciences and its competitors. This is near median its historical median of 84.51. Over the past decade, JFL Life Sciences' Days Payable has ranged from 17.75 to 141.53. According to the industry distribution chart, JFL Life Sciences ranks #500 out of 922 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is JFL Life Sciences' Days Payable too high?
JFL Life Sciences' current Days Payable of 83.56 is near median its 10-year median of 84.51. Over the past 10 years, this metric has ranged from a low of 17.75 to a high of 141.53. The Drug Manufacturers industry median Days Payable is 90.61. JFL Life Sciences' value of 83.56 is 7.8% below this industry median. Based on the distribution chart, JFL Life Sciences ranks #500 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #500 out of 922 companies for Days Payable. This places JFL Life Sciences in the lower half of its industry. The industry median Days Payable is 90.61. JFL Life Sciences' value of 83.56 is 7.8% below this benchmark. Historically, JFL Life Sciences' own Days Payable has ranged from 17.75 to 141.53 over the past decade. While the company's 10-year median is 84.51 vs. the industry median of 90.61, JFL Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current Days Payable of 83.56 is 7.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current Days Payable is 83.56, which is near median its own 10-year median of 84.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.76, compared to a current price of ₹10.45 — trading 70.8% below its estimated fair value. The current Days Payable is 83.56, which is near median its 10-year median of 84.51 and 7.8% below the Drug Manufacturers industry median of 90.61. JFL Life Sciences' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current Days Payable is 83.56 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.45 is trading 70.8% below its estimated GF Value™ of ₹35.76.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
Days Payable: 83.56 (near median its 10-year median of 84.51)
GF Value™: ₹35.76 vs. price of ₹10.45 (70.8% below fair value)
Industry Position: 7.8% below the Drug Manufacturers median (#500 of 922)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
74GF Score
Get the complete analysis for NSE:JFLLIFE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 